Cargando…

STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer

BACKGROUND: High-grade serous carcinoma (HGSC) of the ovary is predominantly diagnosed at late stages and primarily treated with debulking surgery followed by platinum/taxane-based chemotherapy. Although certain patients benefit significantly from currently used chemotherapy, there are patients who...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghaffari, Abdi, Peterson, Nichole, Khalaj, Kasra, Vitkin, Natasha, Robinson, Andrew, Francis, Julie-Ann, Koti, Madhuri
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133940/ https://www.ncbi.nlm.nih.gov/pubmed/30046165 http://dx.doi.org/10.1038/s41416-018-0188-5

Ejemplares similares

Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade–resistant Melanoma for Anti-PD-L1 Rechallenge
por: van der Westhuizen, Andre, et al.
Publicado: (2022)

The Tumor Immune Contexture of Prostate Cancer
por: Vitkin, Natasha, et al.
Publicado: (2019)

Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer
por: Shakfa, Noor, et al.
Publicado: (2023)

CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer
por: Yang, Moran, et al.
Publicado: (2021)

Extracellular vesicle mediated intercellular communication at the porcine maternal-fetal interface: A new paradigm for conceptus-endometrial cross-talk
por: Bidarimath, Mallikarjun, et al.
Publicado: (2017)

291 High Potency STING Agonists Induce Adaptive Immunity-Dependent Curative Responses in an Immune Checkpoint Blockade-Refractory Glioblastoma Model
por: Lea, Spencer, et al.
Publicado: (2023)

Implications of immune dysfunction on endometriosis associated infertility
por: Miller, Jessica E., et al.
Publicado: (2016)

STAT1‐associated intratumoural T(H)1 immunity predicts chemotherapy resistance in high‐grade serous ovarian cancer
por: Au, Katrina K, et al.
Publicado: (2016)

ARIH1 activates STING-mediated T-cell activation and sensitizes tumors to immune checkpoint blockade
por: Liu, Xiaolan, et al.
Publicado: (2023)

Gene networks and expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous ovarian cancer
por: Choi, Jihoon, et al.
Publicado: (2020)

Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers
por: Neal, Adam, et al.
Publicado: (2021)

Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy
por: Wong-Brown, Michelle W., et al.
Publicado: (2022)

Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis
por: Black, Madison, et al.
Publicado: (2016)

STING Agonists as Cancer Therapeutics
por: Amouzegar, Afsaneh, et al.
Publicado: (2021)

C5aR1 blockade reshapes immunosuppressive tumor microenvironment and synergizes with immune checkpoint blockade therapy in high-grade serous ovarian cancer
por: Zhang, Chen, et al.
Publicado: (2023)

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
por: Ilcus, Cristina, et al.
Publicado: (2017)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial
por: Voorwerk, Leonie, et al.
Publicado: (2023)

STING pathway expression in low‐grade serous carcinoma of the ovary: an unexpected therapeutic opportunity?
por: Huvila, Jutta, et al.
Publicado: (2021)

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
por: O’Donnell, Jake S., et al.
Publicado: (2016)

Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection
por: Ou, Huilin, et al.
Publicado: (2022)

Relapsing Polychondritis following PD-1 Blockade by an Immune Checkpoint Inhibitor
por: Mutoh, Tomoyuki, et al.
Publicado: (2023)

Potential for treatment benefit of STING agonists plus immune checkpoint inhibitors in oral squamous cell carcinoma
por: Zhu, Chao, et al.
Publicado: (2021)

Co-delivery of phagocytosis checkpoint and STING agonist by a Trojan horse nanocapsule for orthotopic glioma immunotherapy
por: Zhou, Ying, et al.
Publicado: (2022)

Primary high-grade serous ovarian cancer cells are sensitive to senescence induced by carboplatin and paclitaxel in vitro
por: Uruski, Paweł, et al.
Publicado: (2021)

Discovery of Novel STING Inhibitors Based on the Structure of the Mouse STING Agonist DMXAA
por: Chang, Jiajia, et al.
Publicado: (2023)

Engineered sTRAIL-armed MSCs overcome STING deficiency to enhance the therapeutic efficacy of radiotherapy for immune checkpoint blockade
por: Huang, Kevin Chih-Yang, et al.
Publicado: (2022)

Immunotherapy of alveolar echinococcosis via PD‐1/PD‐L1 immune checkpoint blockade in mice
por: Wang, Junhua, et al.
Publicado: (2018)

Immune checkpoint inhibition improves antimyeloma activity of bortezomib and STING agonist combination in Vk*MYC preclinical model
por: Sokolowska, Olga, et al.
Publicado: (2022)

Interleukin-33 modulates inflammation in endometriosis
por: Miller, Jessica E., et al.
Publicado: (2017)

A balancing act: RNA binding protein HuR/TTP axis in endometriosis patients
por: Khalaj, Kasra, et al.
Publicado: (2017)

Sexual Dimorphism in Outcomes of Non–muscle-invasive Bladder Cancer: A Role of CD163+ Macrophages, B cells, and PD-L1 Immune Checkpoint
por: Chenard, Stephen, et al.
Publicado: (2021)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

Trial watch: STING agonists in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020)

Effects of STING stimulation on macrophages: STING agonists polarize into “classically” or “alternatively” activated macrophages?
por: Ohkuri, Takayuki, et al.
Publicado: (2017)

ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance
por: Jang, Su Chul, et al.
Publicado: (2021)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
por: Koopmans, Iris, et al.
Publicado: (2018)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
por: Wang, Mengjie, et al.
Publicado: (2022)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9u5b35vitf6p0srsjb4sn0jg1o